Clinical Trials Logo

Pediatric Heart Transplantation clinical trials

View clinical trials related to Pediatric Heart Transplantation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02904278 Completed - Clinical trials for Pediatric Heart Transplantation

Novel Mobile Device Application to Improve Adherence

Start date: August 10, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to collect and compare information on how and when adolescent heart transplant recipients take their prescribed medication. The investigators want to find out if regular use of 'an app' on cell phones, called the Teen Pocket PATH® (TPP), can help adolescents take their medication according to their prescribed dosing schedule. This may then help reduce complications of transplant, such as rejection. The investigators also want to find out if how adolescent heart transplant recipients take their medications affects the development of antibodies in their blood. Antibodies are small proteins in the blood that may develop after heart transplantation, and which can sometimes damage a new heart.

NCT ID: NCT02752789 Completed - Clinical trials for Pediatric Heart Transplantation

Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function

Start date: July 15, 2014
Phase:
Study type: Observational

This is a multi-center, prospective, single cohort, observational study of pediatric heart transplant recipients designed to determine the impact of preformed versus de novo human leukocyte antigen (HLA) donor-specific antibodies (DSA), and antibodies to the self-antigens cardiac myosin and vimentin, on chronic allograft function. In addition, the investigators will explore mechanisms of action and predictors of DSA, rejection and altered pathophysiology.

NCT ID: NCT01005316 Completed - Clinical trials for Pediatric Heart Transplantation

Allo-Antibodies in Pediatric Heart Transplantation

Start date: January 2010
Phase: N/A
Study type: Observational

The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity cross-match and to compare them with outcomes in nonsensitized heart transplant recipients.